HELEN HESLOP to Basigin
This is a "connection" page, showing publications HELEN HESLOP has written about Basigin.
Connection Strength
0.108
-
A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. Blood. 2007 Mar 15; 109(6):2657-62.
Score: 0.063
-
Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. Blood. 2001 Oct 01; 98(7):2052-8.
Score: 0.044